Some cancer cells carrying BRAF mutations are highly sensitive to MEK inhibitors, while cells lacking these BRAF mutations or containing RAS or epidermal growth factor receptor (EGFR) mutations are resistant [5, 6]. Here, MAP2K7 is linked to cancer.